IQVIA Holdings Inc. (NYSE:IQV – Get Rating) has been given an average recommendation of “Buy” by the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $277.25.
IQV has been the topic of a number of analyst reports. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Guggenheim initiated coverage on shares of IQVIA in a research note on Monday. They set a “buy” rating and a $244.00 target price on the stock. Wells Fargo & Company cut shares of IQVIA from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $290.00 to $235.00 in a report on Monday, April 25th. Barclays lowered their target price on shares of IQVIA from $275.00 to $240.00 in a report on Thursday, April 28th. Finally, Morgan Stanley reduced their price target on shares of IQVIA from $290.00 to $280.00 and set an “overweight” rating for the company in a research report on Wednesday, February 16th.
Institutional investors and hedge funds have recently bought and sold shares of the company. Gradient Investments LLC grew its position in shares of IQVIA by 5.7% during the first quarter. Gradient Investments LLC now owns 64,359 shares of the medical research company’s stock worth $14,880,000 after buying an additional 3,450 shares in the last quarter. Ninety One UK Ltd grew its position in shares of IQVIA by 13.8% during the first quarter. Ninety One UK Ltd now owns 975,488 shares of the medical research company’s stock worth $225,543,000 after buying an additional 118,139 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of IQVIA by 243.2% during the first quarter. EverSource Wealth Advisors LLC now owns 151 shares of the medical research company’s stock worth $35,000 after buying an additional 107 shares in the last quarter. Advisory Services Network LLC boosted its holdings in IQVIA by 59.9% in the first quarter. Advisory Services Network LLC now owns 6,309 shares of the medical research company’s stock worth $1,459,000 after purchasing an additional 2,364 shares during the period. Finally, Capital Research Global Investors boosted its holdings in IQVIA by 12.7% in the first quarter. Capital Research Global Investors now owns 1,442,596 shares of the medical research company’s stock worth $333,543,000 after purchasing an additional 162,879 shares during the period. Institutional investors own 87.12% of the company’s stock.
IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.07. The firm had revenue of $3.57 billion for the quarter, compared to analyst estimates of $3.54 billion. IQVIA had a net margin of 7.69% and a return on equity of 28.80%. IQVIA’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.05 earnings per share. As a group, analysts predict that IQVIA will post 9.49 earnings per share for the current fiscal year.
IQVIA Company Profile (Get Rating)
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.